Last reviewed · How we verify
NCT03819374
Improving HIV/Tuberculosis Outcomes in Irkutsk
trial in Tuberculosis in 53 participants. Completed in 30 April 2021.
30 May 2020
Quick facts
| Lead sponsor | University of Virginia |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 53 |
| Start date | 15 April 2018 |
| Primary completion | 30 May 2020 |
| Estimated completion | 30 April 2021 |
| Sites | 1 location across Russia |
Conditions studied
- Tuberculosis — all drugs for Tuberculosis →
- HIV Infections — all drugs for HIV Infections →
- Substance Use — all drugs for Substance Use →
Sponsor
University of Virginia
Who can join
Adults 18 to 64, any sex, with Tuberculosis or HIV Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators propose to examine the prospective influence of substance use patterns on HIV/tuberculosis adherence, pharmacokinetics and disease progression while developing novel methods for early detection and correction of these mechanisms of treatment failure in Irkutsk. At the University of Virginia, the investigators have considerable research experience with vulnerable HIV populations and have adapted mobile phone methods for data collection of adherence, substance use, and study retention. The investigators have also begun development of colorimetric methods for pharmacokinetic monitoring that utilizes urine which may be suitable as a non-invasive sample for the unique environmental factors affecting HIV patients in Irkutsk, namely geographic remoteness and concurrent substance use
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Implementation of a Mobile Health Strategy to Improve Linkage to and Engagement with HIV Care for People Living with HIV, Tuberculosis, and Substance Use in Irkutsk, Siberia.
Hodges J, Zhdanova S, Koshkina O, Suzdalnitsky A, et al · · 2021 · cited 11× · PMID 33538649 · DOI 10.1089/apc.2020.0233 -
Process evaluation for the adaptation, testing and dissemination of a mobile health platform to support people with HIV and tuberculosis in Irkutsk, Siberia.
Hodges J, Waldman AL, Koshkina O, Suzdalnitsky A, et al · · 2022 · cited 8× · PMID 35351714 · DOI 10.1136/bmjopen-2021-054867
Verify or expand the search:
- PubMed search for NCT03819374
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tuberculosis
Currently open trials in the same condition.
- NCT05917210 — Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda · NA · recruiting
- NCT07170735 — Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level · recruiting
- NCT07484490 — Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis · NA · recruiting
- NCT06318416 — Precision Rifampin Trial for Personalized Dosing · Phase 1 · recruiting
- NCT07170800 — A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets · Phase 2 · recruiting
Other University of Virginia trials
Trials by the same sponsor.
- NCT05880355 — Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI · EARLY_PHASE1 · not yet recruiting
- NCT07405645 — Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy · NA · recruiting
- NCT07146685 — Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study · Phase 4 · not yet recruiting
- NCT07298941 — Resilience Enhancement Following Sleep Treatment · Phase 2 · recruiting
- NCT07036315 — Meaning in Music-Based Pain Modulation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03819374 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Virginia
- Last refreshed: 9 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03819374.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing